<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00543686</url>
  </required_header>
  <id_info>
    <org_study_id>165/07/FFM</org_study_id>
    <nct_id>NCT00543686</nct_id>
  </id_info>
  <brief_title>Leukotriene Receptor Antagonists or Steroids in Pre-School Asthma</brief_title>
  <acronym>LOS</acronym>
  <official_title>A Randomised Controlled Open-Label Phase IV Mono Centre Study to Compare the Response Profiles of Montelukast Versus Fluticasone in Children With Pre-School Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Explorative comparison of montelukast with inhaled steroids (fluticasone) to estimate
      responder profiles, in terms of symptom scores, rescue medication, increase of FEV1, in
      correlation to presence of allergy, bronchial hyperreactivity (PD20), exhaled NO, excretion
      of leukotrienes, response to RABA and laboratory parameters in patients with pre-school
      asthma i.e. asthma phenotypes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary efficacy variable is the number of responders with a very good asthma symptom control defined as requiring no rapid acting beta agonist (RABA) between the 2. and 6th week of intervention (end of trial)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>the number of patients requiring at least five times RABA between the 2. and 6th week, the number of patients with an increase of FEV1 7.5%, the symptom score, symptom free days, rescue medication, presence of allergy RAST &gt; 2, concentration of eNO, PD20</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Montelukast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fluticasone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast</intervention_name>
    <description>Intake of Montelukast</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone</intervention_name>
    <description>Intake of Fluticasone</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients age 4 -6 years

          -  Diagnosis of mild intermittent bronchial asthma (Step I-II) in the past 6 - 12 months
             as stated by the investigator:

          -  Use of inhaled beta-2-agonists &lt; 1/week (max 3 puff /d)

          -  Exacerbation-free interval &gt; 4 weeks prior to visit 1

          -  The written informed consent of parents after received written and oral information
             about the aim, purpose and risks of the study must be present

        Exclusion Criteria:

          -  Asthma severity ≥ Step 2

          -  Severe concomitant diseases

          -  Suspected non-compliance

          -  age below 4 and age above 7 years

          -  last study participation &lt; 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Zielen, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johann Wolfgang Goethe-University Frankfurt, Zentrum für Kinderheilkunde I, Haus 32, Abt. Pneumologie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Goethe University, Department of Pulmonology</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2007</study_first_submitted>
  <study_first_submitted_qc>October 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2007</study_first_posted>
  <last_update_submitted>February 3, 2009</last_update_submitted>
  <last_update_submitted_qc>February 3, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2009</last_update_posted>
  <responsible_party>
    <name_title>Prof Stefan Zielen</name_title>
    <organization>Goethe University, Childrens Hospital, Dpt of Pulmonology, Frankfurt</organization>
  </responsible_party>
  <keyword>Pre-School Asthma</keyword>
  <keyword>Responder Profiles</keyword>
  <keyword>Fluticasone</keyword>
  <keyword>Montelukast</keyword>
  <keyword>Leukotriene</keyword>
  <keyword>Children with Pre-School Asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Montelukast</mesh_term>
    <mesh_term>Leukotriene Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

